Compendium of Cancer Genome Aberrations

Changes

KIT (view source)

Revision as of 14:32, 12 December 2023

2,670 bytes added ,  14:32, 12 December 2023
no edit summary
Line 7: Line 7:  
==Synonyms==
 
==Synonyms==
   −
Put your text here
+
"KIT Proto-Oncogene Receptor Tyrosine Kinase"; "V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog";  PBT; "Stem Cell Factor Receptor"; SCFR; "Cellular KIT"; C-Kit; CD117; MASTC
−
 
  −
EXAMPLE: Tumor protein p53, ''LFS1, p53, BCC7, TRP53''
      
==Genomic Location==
 
==Genomic Location==
   −
'''Cytoband:''' Put your text here. EXAMPLE: 17p13.1
+
'''Cytoband:''' 4q12
    
'''Genomic Coordinates:'''  
 
'''Genomic Coordinates:'''  
   −
Put your text here
+
chr4:55,524,085-55,606,881(GRCh37/hg19)
 +
 
 +
chr4:55,524,085-55,606,881(GRCh37/hg19)
 +
 
 +
==Cancer Category/Type==
 +
 
 +
KIT mutations are prevalent in many cancers, including gastrointestinal stromal tumors (GIST, a soft tissue sarcoma) (90%)[3], genetical tract cancers (22%), hematopoietic and lymphoid cancers (13.8%), and Melanomas (7%) ([https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=kit see COSMIC]). 
 +
 
   −
EXAMPLE: chr17:7,571,720-7,590,868 [hg19]
+
[http://www.ccga.io/index.php/HAEM4:Acute_Myeloid_Leukemia_(AML)_and_Related_Precursor_Neoplasms Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]
   −
EXAMPLE: chr17:7,668,402-7,687,538 [hg38]
+
- [http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1]
   −
==Cancer Category/Type==
+
- [http://www.ccga.io/index.php/Acute_Myeloid_Leukemia_(AML)_with_inv(16)(p13.1q22)_or_t(16;16)(p13.1;q22) CBFB-MYH11 Acute Myeloid Leukemia (AML) with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11]
 +
 
 +
Mutations that cause constitutive activation of KIT are detected in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity and point mutations in the kinase domain that result in a constitutively activated kinase.
 +
 
 +
Mutations of KIT have been shown to have prognostic significance among AML with t(8;21)(q22;q22) (RUNX1-RUNXT1) and inv(16)(p13.1q22)/ t(16;16)(p13.1;q22) (CBFB-MYH11), in which they are associated with a poor prognosis.  These KIT mutations most commonly occur within exon 8 and 17. [1].  KIT mutations occurs primarily in a subset of leukemias containing inv(16) or t(8;21), so-called core factor binding AML. Apart from exon 17 mutations, also internal tandem duplications in exon 11 have been described. Prognosis. Presence of D816V mutation in KIT is a poor prognostic factor [[http://atlasgeneticsoncology.org/Genes/KITID127.html see Atlas of Genetics and Cytogenetics in Oncology and Haematology]].
 +
 
 +
 
 +
GIST (gastrointestinal stromal tumors)
 +
 
 +
 
 +
Mast cell disease
 +
 
 +
 
 +
Melanoma
   −
Put your text here
+
[http://www.ccga.io/index.php/Melanoma_skin_Cancer Melanoma Skin Cancer]
    
==Gene Overview==
 
==Gene Overview==
   −
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. ([https://www.uniprot.org/uniprot/P10721 adapted from UniProt Description]).
+
The KIT gene encodes tyrosine kinase protein receptor  and is the human homolog of the proto-oncogene first described in the feline sarcoma virus, v-KIT.  Stem Cell Factor protein (SCF) is the ligand which binds to Kit protein, causing dimerization and activation of signaling cascades which are involved in a wide variety of cellular roles including:  regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis.  Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myeloid leukemia, and other diseases  The Kit protein . ([https://www.uniprot.org/uniprot/P10721 adapted from UniProt Description]).
    
==Common Alteration Types==
 
==Common Alteration Types==
   −
Put your text here and/or fill in the table with an X where applicable
+
Mutations in KIT are found clustered in the C-terminal tyrosine kinase domain, the majority occurring at position D816 ([https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=kit see COSMIC]). .  The presence of the KIT D816V mutation in malignaicies confers Imatinib resistance [4]. In AML, the most common KIT mutations are in-frame, internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. 
    
{| class="wikitable sortable"
 
{| class="wikitable sortable"
Line 39: Line 57:  
! Copy Number Loss  !! Copy Number Gain  !!  LOH  !!  Loss-of-Function Mutation  !!  Gain-of-Function Mutation  !!  Translocation/Fusion  
 
! Copy Number Loss  !! Copy Number Gain  !!  LOH  !!  Loss-of-Function Mutation  !!  Gain-of-Function Mutation  !!  Translocation/Fusion  
 
|-
 
|-
−
| EXAMPLE: X ||EXAMPLE: X || EXAMPLE: X  || EXAMPLE: X || EXAMPLE: X || EXAMPLE: X
+
| ||  ||   || || X ||  
 
|}
 
|}
    
==Internal Pages==
 
==Internal Pages==
   −
Put your text here
  −
  −
EXAMPLE [[Germline Cancer Predisposition Genes]]
      
==External Links==
 
==External Links==
−
  −
Put your text here - Include as applicable links to: 1) Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2) COSMIC, 3) CIViC, 4) St. Jude ProteinPaint, 5) Precision Medicine Knnowledgebase (Weill Cornell), 6) Cancer Index, 7) OncoKB, 8) My Cancer Genome, 9) UniProt, 10) Pfam, 11) GeneCards, 12) GeneReviews, and 13) Any gene-specific databases.
  −
  −
EXAMPLES
      
'''[http://atlasgeneticsoncology.org/Genes/KITID127.html ''KIT'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
 
'''[http://atlasgeneticsoncology.org/Genes/KITID127.html ''KIT'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
Line 74: Line 85:  
'''[http://pfam.xfam.org/protein/P10721 ''KIT'' by Pfam]''' - gene and protein structure and function information
 
'''[http://pfam.xfam.org/protein/P10721 ''KIT'' by Pfam]''' - gene and protein structure and function information
   −
'''[http://www.genecards.org/cgi-bin/carddisp.pl?gene=kit ''TP53'' by GeneCards]''' - general gene information and summaries
+
'''[http://www.genecards.org/cgi-bin/carddisp.pl?gene=kit ''KIT'' by GeneCards]''' - general gene information and summaries
    
'''[https://www.ncbi.nlm.nih.gov/gene/3815 ''KIT'' by NCBI Gene]''' - general gene information and summaries
 
'''[https://www.ncbi.nlm.nih.gov/gene/3815 ''KIT'' by NCBI Gene]''' - general gene information and summaries
Line 89: Line 100:     
2. Schafer, E.S. . et al. (2015). Molecular Genetics of Acute Lymphoblastic Leukemia in The Molecular Basis of Cancer, 4th edition. Mendelsohn, J, Howley, PM, Israel, MA, Gray, JW, Thompson, CB. Editors. Elsevier Press: Philadelphia, USA, p395-406.
 
2. Schafer, E.S. . et al. (2015). Molecular Genetics of Acute Lymphoblastic Leukemia in The Molecular Basis of Cancer, 4th edition. Mendelsohn, J, Howley, PM, Israel, MA, Gray, JW, Thompson, CB. Editors. Elsevier Press: Philadelphia, USA, p395-406.
 +
 +
3. Rubin B.P et al. (2001).  KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61: 8118-21.  PMID: 11719439
 +
 +
4. Da Silva Figueiredo Celestino Gomes, P. et al., (2016). PLoS One 11:e0160165.  PMID 27467080  doi: 10.1371/journal.pone.0160165.
    
== Notes ==
 
== Notes ==
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/4774...13617"